Skip to content
value.today

CytoPherx, Inc.

🇺🇸 Ann Arbor, Michigan, USABiotechnologyFounded 2007
Total raised
$35 M
4 rounds on record
Latest round
$5 M
Jul 2020
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of CytoPherx, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$5 MNo. 4$2 to $10 million

CytoPherx, Inc.: Raise no. 4, Jul 2020

Investors in this round

4 investors had bought by the notice of Dec 29, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Schlorff · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes cash payment in the amount of $5,025,000 and cancellation and satisfaction of debt in the amount of $244,160.”

Signed by Eric Schlorff, President. Source: SEC Form D, newest notice filed Dec 29, 2020. Read the notice at the SEC.

equitySEC
Sep 2011$16 MNo. 3$10 to $50 million

CytoPherx, Inc.: Raise no. 3, Sep 2011

Investors in this round

23 investors had bought by the notice of Jan 11, 2012: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $34 M offered; $17 M still to sell
Smallest investment taken
$12,500
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark James Morsfield · Executive Officer
  • R James Danehy · Executive Officer, Director
  • Alvin David Vitangcol · Director
  • H David Humes · Director
  • Kenneth David Van Heel · Director
  • Leslie David Bottorff · Director
  • Peter David DeComo · Director
  • William David White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to the equity securities sold in the offering, the Company issued a Warrant in consideration for a loan commitment.”

Signed by Mark R. Morsfield, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 11, 2012. Read the notice at the SEC.

equity, optionsSEC
Jun 2010$12 MNo. 2$10 to $50 million

CytoPherx, Inc.: Raise no. 2, Jun 2010

Investors in this round

5 investors had bought by the notice of Jun 17, 2010: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered; $0 M still to sell
Smallest investment taken
$250,000
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark R. Morsfield · Executive Officer
  • R. James Danehy · Executive Officer, Director
  • H. David Humes · Director
  • Mina Patel Sooch · Director
  • William David White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark R. Morsfield, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 17, 2010. Read the notice at the SEC.

equity, debt, optionsSEC
Oct 2009$2 MNo. 1$2 to $10 million

CytoPherx, Inc.: Raise no. 1, Oct 2009

Investors in this round

5 investors had bought by the notice of Nov 6, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$235,294
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark R. Morsfield · Executive Officer
  • R. James Danehy · Executive Officer, Director
  • H. David Humes · Director
  • Hugo David Braun · Director
  • Mina Patel Sooch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark R. Morsfield, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 6, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CytoPherx, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2020).

    SEC Form D · Dec 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2020

That is all the official record says: CytoPherx, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of CytoPherx, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CytoPherx, Inc.
NameRoleNamed in
Eric SchlorffExecutive officerDec 2020
Mark James MorsfieldExecutive officerJan 2012
R James DanehyExecutive officerJan 2012
Mark R. MorsfieldExecutive officerJun 2010
R. James DanehyExecutive officerJun 2010
Eric SchlorffDirectorDec 2020
Alvin David VitangcolDirectorJan 2012
H David HumesDirectorJan 2012
Kenneth David Van HeelDirectorJan 2012
Leslie David BottorffDirectorJan 2012
Peter David DeComoDirectorJan 2012
R James DanehyDirectorJan 2012
William David WhiteDirectorJan 2012
H. David HumesDirectorJun 2010
Mina Patel SoochDirectorJun 2010
R. James DanehyDirectorJun 2010
Hugo David BraunDirectorNov 2009